Adoptive cell therapies (ACT) have become a transformative force in cancer immunology, offering powerful platforms for targeting both hematological and ...

Liver fibrosis in the course of metabolic dysfunction-associated steatohepatitis (MASH) could be significantly reduced using CAR T-cells generated in vivo. Scientists at the Icahn School of Medicine ...

Cabaletta Bio (CABA) advances engineered cell therapies for autoimmune disease; insider buying boosts confidence. Click here ...

Marginal zone lymphoma treatment evolves with promising CAR T-cell therapies, addressing unmet needs in aggressive cases and improving patient outcomes.

Precision DNA editing gene therapy achieves deep remissions in aggressive leukemia previously considered incurable.

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

Amid growing evidence suggesting circadian rhythms play a critical in the safety and efficacy of CAR T-cell therapy, ...

Recent advancements include targeted agents, immunotherapy, and fertility-sparing surgeries for patients with advanced ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

Carvykti sales surge, MRD FDA guidance speeds label expansion, and strong cash runway. Click for more on LEGN stock.

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer: instead of going after cancer cells ...